The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force

J Am Acad Dermatol. 2006 May;54(5):818-23. doi: 10.1016/j.jaad.2006.01.054.
No abstract available

Publication types

  • Review

MeSH terms

  • Administration, Topical
  • Calcineurin Inhibitors*
  • Clinical Trials as Topic
  • Dermatitis, Atopic / drug therapy*
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / therapeutic use*
  • Neoplasms / chemically induced*
  • Risk Factors
  • Safety
  • Tacrolimus / administration & dosage
  • Tacrolimus / adverse effects*
  • Tacrolimus / analogs & derivatives*
  • Tacrolimus / therapeutic use*
  • United States
  • United States Food and Drug Administration

Substances

  • Calcineurin Inhibitors
  • Immunosuppressive Agents
  • pimecrolimus
  • Tacrolimus